Trial Profile
A retrospective study assessing the impact of Immune-Checkpoint Inhibitors on long term disease course of and development of Microscopic Colitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jul 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Cancer; Carcinoma; Duodenal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Rectal cancer; Renal cell carcinoma; Small cell lung cancer; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions
- 05 Jul 2021 New trial record
- 23 May 2021 Results presented at the Digestive Disease Week 2021